Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Novo Nordisk

Hims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFs

The U.S. Food and Drug Administration’s recent enforcement action against drug promotion is sending ETFs with exposure to weight-loss treatment manufacturers into question.

Benzinga

Novo Nordisk Poised For UNH-Style Comeback: New Data & AI Boost Signal Reversal

Novo Nordisk A/S (NYSE:NVO) looks ready to shake off its slump. With weight-loss pills showing blockbuster results, Ozempic proving heart-healthy benefits, and analysts flipping bullish, the stock is starting to resemble UnitedHealth Group Inc.'s (NYSE:UNH) rebound playbook.

Benzinga

Novo Nordisk's Wegovy Outperforms Eli Lilly's Tirzepatide In Reducing Risk Of Heart Attack, Stroke, And Death: Study

Novo Nordisk A/S (NYSE:NVO) presented data from the STEER real-world study of evidence gathered from actual patient experiences at the European Society of Cardiology (ESC) Congress 2025.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

'Offices Need To Start Feeling A Little Bit More Like Hotels,' Behind One CBRE Exec's Approach To The Future Of In-Person Work

Within the last month, Paramount, Microsoft (NASDAQ:MSFT), and Novo Nordisk (NYSE:NVO) have announced return-to-office mandates. The companies join other major employers like Amazon (NASDAQ:AMZN), ATT (NYSE:T), and Disney (NYSE:DIS) in requiring that employees work in-person for at least half the week.

Benzinga

Novo Nordisk shares climb after positive anti-obesity pill results

Danish drugmaker jumps by about £9bn as trial shows ‘significant weight loss’ with tablet version of Wegovy

The Guardian - UK

New trial explores if weight-loss ingredient could help fight Alzheimer’s

The trials represent the first large-scale studies investigating the ingredient’s impact on the most common type of dementia

The Independent UK

Ozempic Lawsuit: Everything You Need To Know About The Latest Vision Loss Allegations

Ozempic lawsuit: Latest vision loss allegations explained. Learn about potential stomach paralysis & gastroparesis claims. Is there a connection?

Bored Panda

Read news from The Economist, FT, and more,
with one subscription

Weight-loss drugs help stop intrusive thoughts about food, study finds

Wegovy also was found to improve mental health, self-confidence and the development of healthier habits

The Independent UK

Stock Of The Day: Is The Novo Nordisk Death Spiral Finally Over?

Novo Nordisk A/S (NYSE:NVO) is trading higher on Friday. It is just below resistance around the $58 level.

Benzinga

Wegovy's Next Step: Novo Nordisk Eyes Approval for Higher-Dose Treatment

Novo Nordisk A/S (NYSE:NVO) reportedly said on Tuesday that it intends to seek US regulatory approval for a high-dose version of its weight-loss injection Wegovy (semaglutide), another effort to counter Eli Lilly and Co. (NYSE:LLY).

Benzinga

What's Going On With Novo Nordisk Shares Monday?

Novo Nordisk A/S (NYSE:NVO) shares are trading higher Monday after the company announced European Union approval for oral semaglutide to reduce cardiovascular death, heart attack and stroke.

Benzinga

Here's Novo Nordisk's First Oral Obesity Drug In Europe With Proven Heart Health Impact

On Monday, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) approved an update to Novo Nordisk A/S‘ (NYSE:NVO) Rybelsus (oral semaglutide) label to reflect the cardiovascular benefits seen in the SOUL trial.

Benzinga

Giro della Toscana: Isaac del Toro wins with solo attack across Monte Serra

Michael Storer outsprints Steff Cras for runner-up position from two-rider chase

Cycling News

Wegovy And Zepbound Cost Effective But They Could Break Drug Budgets

The Institute for Clinical and Economic Review (ICER) on Tuesday released a Draft Evidence Report assessing the comparative clinical effectiveness and value of Novo Nordisk A/S’ (NYSE:NVO) semaglutide (Wegovy) and Eli Lilly and Co.’s (NYSE:LLY) tirzepatide (Zepbound) for obesity management.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Evening Standard

Ozempic maker to slash 9,000 jobs globally as competition intensifies

Novo Nordisk’s plans would result in around 11% of the pharmaceutical giant’s 78,400-strong workforce being axed.

Euronews

Novo Nordisk to cut 9,000 jobs as Eli Lilly competition intensifies

The pharmaceutical giant will axe over 11% of its global workforce as rival Eli Lilly gathers market share in the obesity drug market.

The Independent UK

Weight loss drugmaker to slash 9,000 jobs in £926 million cost cut

Novo Nordisk was at one point last year Europe's most valuable listed company

Benzinga

Novo Nordisk To Cut 9,000 Jobs As Competition From Eli Lilly Heats Up: Analyst Calls Move 'Tough, Natural...Very Necessary'

Novo Nordisk (NYSE:NVO) has announced a significant restructuring plan that will see the company cut 9,000 jobs, representing 11.5% of its workforce. The decision comes as the pharmaceutical giant faces mounting pressure from U.S. competitor Eli Lilly (NYSE:LLY).

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Novo Nordisk, maker of obesity drug Wegovy, to cut 9,000 jobs to sharpen focus, meet competition

Danish pharmaceutical company Novo Nordisk, maker of weight-loss drug Wegovy, said Wednesday it would cut 9,000 jobs, 5,000 of them in Denmark, in order to strengthen the company’s focus on growth opportunities in obesity and diabetes medications

The Guardian - UK

Wegovy maker Novo Nordisk to cut 9,000 jobs amid increased competition

Danish manufacturer of weight-loss and diabetes drugs under pressure from US rival Eli Lilly

The Guardian - UK

Trump reportedly asks EU to levy 100% tariffs on India and China; Ozempic maker Novo to cut 9,000 jobs – as it happened

US president wants to up pressure on Russia to end war in Ukraine

Benzinga

Ozempic Is The New Botox And Big Pharma Is Printing Billions

Ozempic and Zepbound have morphed from diabetes treatment into a cultural phenomenon, helping Novo Nordisk A/S (NYSE:NVO) and Eli Lilly And Co (NYSE:LLY) achieve a combined market cap topping $900 billion. Celebrities flaunt it, Silicon Valley elites swear by it, and analysts predict the GLP-1 market could surpass $150 billion…

The Independent UK

WHO has added GLP-1 drugs to the essential medicines list. Here’s what that means

GLP-1 drugs were initially developed for diabetes, but have become wildly popular weight-loss drugs too

The Independent UK

Scientists say there is no link between ‘microdosing’ weight-loss drugs and living longer

It is ‘too early’ to know whether small doses of weight-loss drugs can help you live longer, experts say

Benzinga

After Copycat Boom, China's Drugmakers Target Global Generics

China-based drugmakers that once fueled a surge of copycat weight-loss treatments in the U.S. are now pivoting to generics of Novo Nordisk‘s (NYSE:NVO) Wegovy and Eli Lilly's (NYSE:LLY) Zepbound as regulators tighten rules on compounded medicines.

1 … 6 7 8 9

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.